Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2004-12-06
2008-08-05
Priebe, Scott D (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000, C435S456000, C536S024100, C424S093200, C514S04400A
Reexamination Certificate
active
07407801
ABSTRACT:
The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.
REFERENCES:
patent: 5168062 (1992-12-01), Stinski
patent: 5385839 (1995-01-01), Stinski
patent: 5849522 (1998-12-01), Fleckenstein et al.
patent: 5872005 (1999-02-01), Wang et al.
patent: 6218140 (2001-04-01), Fleckenstein et al.
patent: 2004/0038402 (2004-02-01), Antoniou et al.
patent: WO 2003014298 (2003-02-01), None
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, issued by the U.S. National Institutes of Health, Dec. 7, 1995.
Driskell et al., “Current status of gene therapy for inherited lung diseases,” Annu. Rev. Physiol. 65: 585-612, 2003.
Isomura H, Tsurumi T, Stinski MF. “Role of the proximal enhancer of the major immediate-early promoter in human cytomegalovirus replication,” J Virol. Dec. 2004;78(23):12788-99.
Isomura H, Stinski MF. “The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection,” J Virol. Mar. 2003;77(6):3602-14.
Meier JL, Keller MJ, McCoy JJ. “Requirement of multiple cis-acting elements in the human cytomegalovirus major immediate-early distal enhancer for viral gene expression and replication,” J Virol. Jan. 2002;76(1):313-26.
Ostedgaard LS, Zabner J, Vermeer DW, Tokhlina T, Karp PH, Stecenko AA, Randak C, and Welsh MJ. CFTR With a Partially Deleted R Domain Corrects the Cystic Fibrosis Chloride Transport Defect in Human Airway Epithelia In Vitro and in Mouse Nasal Mucosa In Vivo . Proc. Natl. Acad. Sci. USA, 99: 3093-3098, 2002.
Davies et al., 2001, “Gene therapy for cystic fibrosis,” J. Gene Med. 3:409-417.
Ostegaard et al., 2001, “Regulation of the cystic fibrosis transmembrane conductance regulator CI-channel by its R domain,” J. Biol. Chem. 276:7689-92.
Csanady et al., 2000, “Severed channels probe regulation of gating of cystic fibrosis transmembrane conductance regulator by its cytoplasmic domains,” J. Gen. Physiol. 116:477-500.
Meier JL, Pruessner JA. “The human cytomegalovirus major immediate-early distal enhancer region is required for efficient viral replication and immediate-early gene expression,” J Virol. Feb. 2000;74(4):1602-13.
Ostedgaard, et al., 2000, “A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution,” Proc. Natl. Acad. Sci. U.S.A. 97:5657-62.
Zabner et al., 2000, “Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer,” J. Virol. 74:3852-8.
Rabinowitz et al., 2000, “Building a better vector: the manipulation of AAV virions,” Virology 278:301-308.
Xie et al., 2000, “Conformation, independent of charge, in the R domain affects cystic fibrosis transmembrane conductance regulator channel openings,” Biophys. J. 78:1293-1305.
Chiorini et al., 1999, “Cloning and characterization of adeno-associated virus type 5,” J. Virol. 73:1309-1319.
Wang et al., 1999, “Efficient CFTR expression from AAV vectors packaged with promoters—the second generation,” Gene Therapy 6:667-675.
Flotte, 1999, “Gene therapy for cystic fibrosis,” Curr. Opin Mol. Ther. 1:510-516.
Welsh, 1999, “Gene transfer for cystic fibrosis,” J. Clin. Invest. 104:1165-1166.
Hernandez et al., “Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model,” 1999, J. Virol. 73:8549-8558.
Stinski, 1999, Cytomegalovirus promoter for expression in mammalian cells. In Gene Expression Systems: Using Nature for the Art of Expression. Academic Press, New York. pp. 211-233.
Vankeerberghen et al., 1999, “Functional characterization of the CFTR R domain using CFTR/MDR1 hybrid and delection constructs,” Biochemistry 38:14988-998.
Zhang et al., 1998, “Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes,” Proc. Natl. Acad. Sci. USA 95:10158-163.
Ma et al., 1997, “Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel,” J. Biol. Chem. 272:28133-34.
Yew et al., 1997, “Optimization of plasmid vectors for high-level expression in lung epithelial cells,” Human Gene Therapy 8:575-84.
Dong et al., 1996, “Quantitative analysis of the packaging capacity of recombinant adeno-associated virus,” Human Gene Therapy 7: 2101-12.
Jiang et al., 1996, “Ability of adenovirus vectors containing different CFTR transcriptional cassettes to correct ion transport defects in CF cells,” Am. J. Physiol. 271:L527-37.
Phelps et al., 1995, “Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice,” Hum. Mol. Genet. 4:1251-8.
Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited diseases. 7th ed. New York: McGraw-Hill, 1995:3799-876.
Flotte et al., 1993, “Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter,” J. Biol. Chem. 268:3781-3790.
Rich et al., 1993, “Effect of deletion mutations on the functions of CFTR chloride channels,”Receptors Channels 1:221-232.
Rich et al., 1991, “Effect of deleting the R domain on CFTR-generated chloride channels,” Science 253:205-7.
Levitt et al., 1989, “Definition of an efficient synthetic poly(A) site,” Genes Dev. 3:1019-25.
Riordan et al., 1989, “Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA,” Science 245:1066-73.
Stinski and Roehr, 1985, “Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components,” J. Virol. 55:431-41.
Chiorini John A.
Ostedgaard Lynda S.
Stinski Mark F.
Welsh Michael J.
McKee Voorhees & Sease, P.L.C.
National Institutes of Health (NIH)
Priebe Scott D
University of Iowa Research Foundation
LandOfFree
Truncated CMV promoters and vectors containing same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated CMV promoters and vectors containing same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated CMV promoters and vectors containing same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3997354